Multiple Sclerosis New Zealand is disappointed Pharmac is only funding treatment for high risk sufferers
Multiple Sclerosis New Zealand is disappointed Pharmac is only funding treatment for high risk sufferers
8 October 2019
Pharmac has announced its funding the Multiple Sclerosis treatment Ocrevus .
MS New Zealand general manager Amanda Rose says the treatment is being prioritised for people who are likely to contract a further condition - which can be life threatening.
But she says lower risk sufferers need to have earlier access to the drug - so their condition doesn't worsen.
© 2024 Newstalk ZB, NZCity